kaal:position:2026-07-31-5101

Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress should be assessed against Kaal's source-bound claim that Industry specific venture capital investment data allows regulators to anticipate regulatory needs in the industries carrying the highest levels of disruptive innovation, and the level of disruptive innovation can be quantified by the venture capital dollars flowing into those industries. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

industry level venture capital investment data is available
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress

Scholarly basis

kaal:claim:2740477-036
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2113
Mapping ambiguous: true

Topics

innovationresearch-methodsdynamic-regulation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0021 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 3d3c8c4167496f9857c2e0e9c08d4e3dd600c09dfc941868e9a8ef4297d36f73
curl -s https://wulfkaal.github.io/positions/2026-07-31-5101.md | sha256sum